Tech Company Financing Transactions

Cardioxyl Pharmaceuticals Funding Round

OrbiMed, Aurora Funds and New Enterprise Associates participated in a $28.1 million Series B venture round for Cardioxyl Pharmaceuticals. The round was announced on 11/7/2012.

Transaction Overview

Company Information

Company Status

Acquired or Merged

Industry

Biopharmaceutical

Mailing Address

1450 Raleigh Rd. 212
Chapel Hill, NC 27517
USA

Phone

(919) 869-8585

Website

www.cardioxyl.com

Email Address

[email protected]

Overview

Cardioxyl Pharmaceuticals' mission is the discovery and development of newclasses of safe and effective therapeutic agents for the treatment ofcardiovascular disease. Cardioxyl's initial program is a novel medication forthe treatment of acute decompensated heart failure.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Christopher Kroeger

        

Chief Medical Officer

Shi Foo

        

Chief Scientific Officer

John Reardon

        

VP - Regulatory Affairs

Doug Cowart

        

Browse more venture capital transactions:

Prev: 11/7/2012: ClearView Audio venture capital transaction
Next: 11/7/2012: The One-Page Company venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary